Document Detail


Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa.
MedLine Citation:
PMID:  23407225     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess the clinical utility and cost of point-of-care Xpert® MTB/RIF for the diagnosis of smear-negative tuberculosis (TB).
DESIGN: Cohort study of smear-negative TB suspects at a South African primary care clinic. Participants provided one sputum sample for fluorescent smear microscopy and culture and an additional sample for Xpert. Outcomes of interest were TB diagnosis, linkage to care, patient and provider costs.
RESULTS: Among 199 smear-negative TB suspects, 16 were positive by Xpert, 15 by culture and 7 by microscopy. All cases identified by Xpert began anti-tuberculosis treatment the same or next day; only one of five Xpert-negative culture-positive cases started treatment after 34 days. Xpert at point of care offered similar diagnostic yield but a faster turnaround time than smear and culture performed at a centralized laboratory. Compared to smear plus culture, Xpert (at US$9.98 per cartridge) was US$3 less expensive per valid result (US$21 vs. US$24) and only US$6 more costly per case identified (US$266 vs. US$260).
CONCLUSION: Xpert is an effective method of diagnosing smear-negative TB. It is cost saving for patients, especially if performed at point of care, but it is costly for health care providers. Data-driven studies are needed to determine its cost-effectiveness in resource-poor settings with diverse diagnostic practices.
Authors:
A Van Rie; L Page-Shipp; C F Hanrahan; K Schnippel; H Dansey; J Bassett; K Clouse; L Scott; W Stevens; I Sanne
Related Documents :
3328565 - In vitro chemosensitivity of plasmodium falciparum to four chloroquine derivatives.
21728745 - Colonization of pressure ulcers by multidrug-resistant microorganisms in patients recei...
9562475 - Glial tau pathology in neurodegenerative diseases: their nature and comparison with neu...
1488405 - The bioinequivalence of carbamazepine tablets with a history of clinical failures.
21975885 - On-site night float by attending physicians: a model to improve resident education and ...
18306855 - The effect of ceramide-containing skin care products on eczema resolution duration.
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease     Volume:  17     ISSN:  1815-7920     ISO Abbreviation:  Int. J. Tuberc. Lung Dis.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-14     Completed Date:  2013-07-26     Revised Date:  2014-06-17    
Medline Journal Info:
Nlm Unique ID:  9706389     Medline TA:  Int J Tuberc Lung Dis     Country:  France    
Other Details:
Languages:  eng     Pagination:  368-72     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Ambulatory Care* / economics
Antitubercular Agents / therapeutic use
Bacteriological Techniques* / economics
Cost-Benefit Analysis
Developing Countries
Female
Health Care Costs
Health Expenditures
Humans
Logistic Models
Male
Mycobacterium tuberculosis / genetics,  isolation & purification*
Odds Ratio
Point-of-Care Systems* / economics
Polymerase Chain Reaction* / economics
Predictive Value of Tests
Primary Health Care* / economics
South Africa
Sputum / microbiology*
Time Factors
Tuberculosis, Pulmonary / diagnosis,  drug therapy,  economics,  microbiology*
Grant Support
ID/Acronym/Agency:
D43 TW009774/TW/FIC NIH HHS; U2RTW007370//PHS HHS
Chemical
Reg. No./Substance:
0/Antitubercular Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uga...
Next Document:  Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldov...